Insider Selling: AngioDynamics, Inc. (NASDAQ:ANGO) Director Sells 6,201 Shares of Stock

AngioDynamics, Inc. (NASDAQ:ANGO – Get Rating) Director Wesley Johnson sold 6,201 shares of the company’s stock in a transaction dated Monday, April 11th. The stock was sold at an average price of $23.00, for a total transaction of $142,623.00. Following the completion of the sale, the director now owns 80,003 shares in the company, valued at approximately $1,840,069. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Shares of NASDAQ ANGO traded up $0.03 during mid-day trading on Wednesday, reaching $23.12. The company’s stock had a trading volume of 10,905 shares, compared to its average volume of 322,294. The stock has a 50-day moving average of $22.48 and a two-hundred day moving average of $24.94. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.61 and a current ratio of 2.59. The stock has a market capitalization of $895.14 million, a P/E ratio of -22.49 and a beta of 0.93. AngioDynamics, Inc. has a 1-year low of $20.03 and a 1-year high of $32.00.

AngioDynamics (NASDAQ:ANGO – Get Rating) last released its quarterly earnings data on Thursday, April 7th. The medical instruments supplier reported $0.03 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.01) by $0.04. AngioDynamics had a negative net margin of 12.99% and a negative return on equity of 0.12%. The company had revenue of $74.00 million during the quarter, compared to the consensus estimate of $76.32 million. During the same quarter in the prior year, the firm earned $0.02 EPS. AngioDynamics’s quarterly revenue was up 3.9% on a year-over-year basis. Analysts predict that AngioDynamics, Inc. will post -0.01 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Exane Derivatives raised its stake in AngioDynamics by 4,883.3% in the fourth quarter. Exane Derivatives now owns 1,495 shares of the medical instruments supplier’s stock valued at $41,000 after buying an additional 1,465 shares in the last quarter. Point72 Hong Kong Ltd increased its holdings in shares of AngioDynamics by 38.8% in the 3rd quarter. Point72 Hong Kong Ltd now owns 1,728 shares of the medical instruments supplier’s stock valued at $45,000 after acquiring an additional 483 shares during the last quarter. Pinebridge Investments L.P. acquired a new stake in shares of AngioDynamics during the 4th quarter worth about $55,000. Concord Wealth Partners lifted its stake in AngioDynamics by 296.3% during the fourth quarter. Concord Wealth Partners now owns 3,396 shares of the medical instruments supplier’s stock worth $94,000 after purchasing an additional 2,539 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale acquired a new position in AngioDynamics in the fourth quarter valued at approximately $100,000. 94.11% of the stock is owned by institutional investors and hedge funds.

Several equities research analysts recently issued reports on ANGO shares. Zacks Investment Research lowered shares of AngioDynamics from a “hold” rating to a “strong sell” rating and set a $21.00 target price for the company. in a report on Tuesday, March 8th. StockNews.com assumed coverage on AngioDynamics in a report on Thursday, March 31st. They issued a “hold” rating for the company. Finally, Canaccord Genuity Group increased their target price on shares of AngioDynamics from $34.00 to $40.00 in a research report on Friday, April 8th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $32.50.

AngioDynamics Company Profile (Get Rating)

AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally.

Featured Stories